Neurocrine End Period Cash Flow from 2010 to 2024
| NBIX Stock | USD 116.08 0.56 0.48% |
End Period Cash Flow | First Reported 1996-03-31 | Previous Quarter 396.3 M | Current Value 139.7 M | Quarterly Volatility 101.4 M |
Check Neurocrine Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neurocrine Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 22.4 M, Interest Expense of 7.4 M or Selling General Administrative of 894.2 M, as well as many indicators such as Price To Sales Ratio of 6.48, Dividend Yield of 0.0 or PTB Ratio of 6.13. Neurocrine financial statements analysis is a perfect complement when working with Neurocrine Biosciences Valuation or Volatility modules.
Neurocrine | End Period Cash Flow |
Latest Neurocrine Biosciences' End Period Cash Flow Growth Pattern
Below is the plot of the End Period Cash Flow of Neurocrine Biosciences over the last few years. It is Neurocrine Biosciences' End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Neurocrine Biosciences' overall financial position and show how it may be relating to other accounts over time.
| End Period Cash Flow | 10 Years Trend |
|
End Period Cash Flow |
| Timeline |
Neurocrine End Period Cash Flow Regression Statistics
| Arithmetic Mean | 147,464,600 | |
| Geometric Mean | 103,500,343 | |
| Coefficient Of Variation | 73.57 | |
| Mean Deviation | 94,143,920 | |
| Median | 115,485,000 | |
| Standard Deviation | 108,488,826 | |
| Sample Variance | 11769.8T | |
| Range | 332.7M | |
| R-Value | 0.87 | |
| Mean Square Error | 2997.6T | |
| R-Squared | 0.76 | |
| Significance | 0.000021 | |
| Slope | 21,197,068 | |
| Total Sum of Squares | 164777.6T |
Neurocrine End Period Cash Flow History
About Neurocrine Biosciences Financial Statements
Neurocrine Biosciences investors use historical fundamental indicators, such as Neurocrine Biosciences' End Period Cash Flow, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Neurocrine Biosciences. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| End Period Cash Flow | 259.1 M | 272.1 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| MSFT | Microsoft | |
| V | Visa Class A | |
| MSFT | Microsoft |
Additional Tools for Neurocrine Stock Analysis
When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.